Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations (NCT04521686)
A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic of Scottsdale — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- Mayo Clinic of Scottsdale — Phoenix, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- USC Norris Cancer Hospital — Los Angeles, California
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Chicago Pritzker School of Medicine — Chicago, Illinois
- Indiana University School of Medicine — Indianapolis, Indiana
- The John Hopkins Hospital — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Memorial Sloan Kettering Cancer Center — Middletown, New Jersey
- Memorial Sloan Kettering Cancer Center — Commack, New York
- Memorial Sloan Kettering Cancer Center — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Sarah Cannon Cancer Center — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
- St Vincent's Hospital Sydney — Darlinghurst, New South Wales
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest — Bordeaux,
- Gustave Roussy — Villejuif,
- Prince of Wales Hospital — Hong Kong, Shatin, New Territories
- National Cancer Center Hospital East — Kashiwa, Chiba
- Kanagawa Cancer Center — Yokohama, Kanagawa
- Osaka University Hospital — Suita-shi, Osaka
- Shizuoka Cancer Center — Nakatogari, Shizuoka
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cholangiocarcinoma
- An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma — Yerevan,
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Santa Monica, California
- [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma — Seattle, Washington
- Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples — Charlottesville, Virginia
- Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid — St Louis, Missouri
Explore by condition: All Cholangiocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.